Trial
NCT01183884
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
—
Condition
Neuroblastoma
Intervention
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Why stopped
Low participant accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-14